CGC News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CG

Mkt Cap

$302.0M

Volume

2.34M

Next Earnings

November 6th

Loading chart

CG

CGCCanopy Growth Corporation Common Shares

CGC

Pay with—

Available Balance0.00

CG

Mkt Cap

$311.1M

Volume

2.34M

Next Earnings

November 6th

Chart Financials Earnings News About Insider Filings

Canopy Growth vs. Tilray Brands: Which Cannabis Stock Is a Better Buy in 2026?The article compares two major cannabis companies navigating industry challenges. Canopy Growth focuses on premium Canadian cannabis and European medical sales but faces internal control weaknesses and significant losses. Tilray Brands has diversified into beverages and international markets, posting record Q1 revenue of $257M with improving margins. The author recommends Tilray as the better choice due to its larger scale, diversified revenue streams, and clearer path to profitability, though both stocks remain risky investments in a volatile industry.The Motley Fool · Oct 15, 2026

Here's Why Canopy Growth Corporation (CGC) Fell More Than Broader MarketCanopy Growth Corporation (CGC) declined 6.27% to $0.71, significantly underperforming the S&P 500's 1.11% loss. The stock has fallen 17.13% over the past month. Upcoming earnings projections show a concerning -$0.03 EPS (down 200% YoY), though revenue is expected to grow 22.09% to $59.12 million. The company holds a Zacks Rank of #3 (Hold).Zacks Investment Research · Oct 14, 2026

Canopy Growth Corporation (CGC) Is a Trending Stock: Facts to Know Before Betting on ItCanopy Growth Corporation (CGC) has been trending on Zacks.com's most searched stocks list. The stock has underperformed the S&P 500 by 19.2% over the past month (-17.1% vs +2.1%). While the company shows revenue growth of 22.1% for the current quarter and has beaten EPS estimates in recent quarters, it remains unprofitable with expected losses. The stock carries a Zacks Rank #3 (Hold) rating and trades at a premium valuation (Grade D), suggesting it may perform in line with the broader market in the near term.Zacks Investment Research · Oct 14, 2026

3 Huge Red Flags From Tilray's Q1 Earnings ReportTilray Brands reported Q1 fiscal 2027 results with concerning fundamentals despite revenue growth. The company's cash burn spiked to $16.5 million (up from $1.3 million year-over-year), core cannabis revenue declined 13%, and operating expenses surged 83%. While top-line growth was driven by acquisitions like BrewDog, organic cannabis business weakness and ballooning costs suggest the stock faces continued headwinds.The Motley Fool · Oct 12, 2026

Canopy Growth vs. Tilray Brands: Which Healthcare Stock Is a Better Buy in 2026?Canopy Growth and Tilray Brands represent diverging strategies in the cannabis industry. Canopy pursues a lean, brand-focused model with emphasis on U.S. expansion, while Tilray has diversified into craft beverages and wellness products. Both companies reported significant net losses in FY 2026 despite revenue growth, with Tilray showing better financial metrics (higher revenue, lower debt-to-equity ratio, higher gross margin) but greater business complexity. The article suggests Tilray may appeal to diversification-focused investors, while Canopy attracts those betting on pure cannabis growth, though both carry substantial risks.The Motley Fool · Oct 10, 2026

UTMD Trades at a Premium to the Industry: How to Play the Stock?Utah Medical Products (UTMD) trades at a premium valuation of 4.05X EV/sales versus industry average of 2.68X. While the company benefits from strong margins (58.2% gross margin), a debt-free balance sheet with $87.5M in cash, and strategic acquisitions, it faces near-term headwinds including 12.3% revenue decline, major customer losses, and projected 10-13% revenue decline for 2026. Long-term investors may hold, but new investors should await a better entry point.Zacks Investment Research · Oct 8, 2026

Why Canopy Growth Corporation (CGC) Dipped More Than Broader Market TodayCanopy Growth Corporation (CGC) declined 1.87% to $0.87, underperforming the S&P 500's 0.22% loss. The stock has fallen 7.75% over the past month. Upcoming earnings are expected to show a loss of $0.03 per share with a 200% year-over-year decline, though revenue is projected to grow 22.09%. The company holds a Zacks Rank of #3 (Hold).Zacks Investment Research · Oct 7, 2026

Canopy Growth Corporation (CGC) Stock Declines While Market Improves: Some Information for InvestorsCanopy Growth Corporation (CGC) declined 1.54% to $0.88 per share, underperforming the broader market which gained modestly. The stock has lost 7.43% over the past month. While revenue is expected to grow 22.09% year-over-year to $59.12 million, earnings are projected to worsen with an EPS of -$0.03 (down 200% from prior year). The company holds a Zacks Rank of #3 (Hold).Zacks Investment Research · Oct 1, 2026

VFF Stock Up 49% in Three Months: Is the Rally Sustainable?Village Farms International (VFF) shares have surged 49% in three months, driven by 15% cannabis sales growth and expanding 51% gross margins, primarily from strong European exports led by Germany. However, the company faces increasing competition from Tilray and Canopy Growth in European markets, pricing pressure from rising industry supply, and heavy dependence on Germany for export growth. While the company holds a Zacks Rank #3 (Hold), investors should await evidence of successful market diversification before committing to longer-term positions.Zacks Investment Research · Oct 1, 2026

Canopy Growth Is Closing in on Positive EBITDA. Should You Buy the Stock?Canopy Growth is approaching positive adjusted EBITDA with Q1 fiscal 2027 revenue up 13% year-over-year to $57.4 million, narrowing adjusted EBITDA losses to $2.3 million from $5.7 million. The MTL Cannabis acquisition is driving growth across Canadian medical, adult-use, and international markets, with expected $7.2 million in annual cost savings. However, free cash flow deteriorated to a $18.5 million outflow, raising concerns about cash generation despite an encouraging balance sheet with $241.4 million in cash.The Motley Fool · Sep 30, 2026

to start trading

CG

CGCCanopy Growth Corporation Common Shares

CGC

Pay with—

Available Balance0.00

Your PositionYou don't own any CGC yet.

Related Tickers

Earnings